A ‘Lobby’ Where a Molecule Mob Tells Genes What to Do
By Philip Ball,
Quanta Magazine
| 02. 14. 2024
The discovery during the Human Genome Project in the early 2000s that we humans have only about 20,000 protein-coding genes — about as many as the tiny soil-dwelling nematode worm, and less than half as many as the rice plant — came as a shock. That blow to our pride was softened, though, by the idea that the human genome is rich in regulatory connections. Our genes interact in a dense network, in which pieces of DNA and the molecules they encode (RNA and proteins) control the “expression” of other genes, influencing whether they make their respective RNA and proteins. To understand the human genome, we needed to understand this process of gene regulation.
That task, however, is proving to be much harder than decoding the sequence of the genome.
Initially, it was suspected that gene regulation was a simple matter of one gene product acting as an on/off switch for another gene, in digital fashion. In the 1960s, the French biologists François Jacob and Jacques Monod first elucidated a gene regulatory process in mechanistic detail: In Escherichia coli bacteria...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...